Replies to post #198812 on Biotech Values

[DewDiligence]

KMDA +8% on phase-2 data in AAT deficiency:

http://finance.yahoo.com/news/kamada-meets-primary-endpoint-u-103000805.html

Note: This trial tested inhaled AAT. In a partnership with SHPG, KMDA sells injected AAT with the brand name, Glassia as a treatment for AAT deficiency.